• Explore /
  • Poster
  • / TRUSTY: A randomized multicenter phase II/III study of trifluridine/tipiracil and bevacizumab versus irinotecan, fluoropyrimidine, and bevacizumab as second-line treatment in patients with metastatic colorectal cancer progressive during or following first-line oxaliplatin-based chemotherapy.

TRUSTY: A randomized multicenter phase II/III study of trifluridine/tipiracil and bevacizumab versus irinotecan, fluoropyrimidine, and bevacizumab as second-line treatment in patients with metastatic colorectal cancer progressive during or following first-line oxaliplatin-based chemotherapy.

Abstract Poster

Authors

null

Takayuki Yoshino

National Cancer Center Hospital East, Kashiwa, Japan

Takayuki Yoshino , Eiji Oki , Hiroaki Nozawa , Takako Eguchi Nakajima , Hiroya Taniguchi , Satoshi Morita , Naruhito Takenaka , Daisuke Ozawa , Kuniaki Shirao

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2018 Gastrointestinal Cancers Symposium

Session Type

Trials in Progress Poster Session

Session Title

Trials in Progress Poster Session C: Cancers of the Colon, Rectum, and Anus

Track

Cancers of the Colon, Rectum, and Anus

Sub Track

Multidisciplinary Treatment

Clinical Trial Registration Number

173618

Citation

J Clin Oncol 36, 2018 (suppl 4S; abstr TPS881)

DOI

10.1200/JCO.2018.36.4_suppl.TPS881

Abstract #

TPS881

Poster Bd #

Q9

Abstract Disclosures

Similar Posters

First Author: Toshiki Masuishi

First Author: Axel Grothey

First Author: T. Hansen

First Author: M. Peeters